Cardiff Oncology, Inc.

NasdaqCM:CRDF Voorraadrapport

Marktkapitalisatie: US$149.2m

Cardiff Oncology Beheer

Beheer criteriumcontroles 3/4

Cardiff Oncology's CEO is Mark Erlander, appointed in May 2020, has a tenure of 4.5 years. total yearly compensation is $1.55M, comprised of 38.4% salary and 61.6% bonuses, including company stock and options. directly owns 0.053% of the company’s shares, worth $78.46K. The average tenure of the management team and the board of directors is 2.8 years and 10.2 years respectively.

Belangrijke informatie

Mark Erlander

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris38.4%
Dienstverband CEO4.5yrs
Eigendom CEO0.05%
Management gemiddelde ambtstermijn2.8yrs
Gemiddelde ambtstermijn bestuur10.2yrs

Recente managementupdates

Recent updates

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Oct 09
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Oct 04

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Jun 19
We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 09

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Mar 03
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Nov 16
Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 01
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Feb 22
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Sep 14

Cardiff Oncology: Down But Not Out

Aug 22

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Jun 07

Cardiff Oncology: Risky Investment

May 19

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Mar 01

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Jan 28
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff: The Pfizer Interest Is Interesting

Dec 15

Circling Back On Cardiff Oncology

Oct 12

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Current Slump Doesn't Look Right

Jun 14

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Apr 29
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

Feb 28
How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Jan 24
What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Analyse CEO-vergoeding

Hoe is Mark Erlander's beloning veranderd ten opzichte van Cardiff Oncology's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$41m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$2mUS$594k

-US$41m

Sep 30 2023n/an/a

-US$41m

Jun 30 2023n/an/a

-US$40m

Mar 31 2023n/an/a

-US$39m

Dec 31 2022US$2mUS$571k

-US$39m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$4mUS$533k

-US$28m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$24m

Dec 31 2020US$1mUS$445k

-US$23m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$20m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$853kUS$399k

-US$17m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$16m

Mar 31 2019n/an/a

-US$19m

Dec 31 2018US$909kUS$387k

-US$19m

Sep 30 2018n/an/a

-US$18m

Jun 30 2018n/an/a

-US$18m

Mar 31 2018n/an/a

-US$20m

Dec 31 2017US$1mUS$374k

-US$25m

Compensatie versus markt: Mark's total compensation ($USD1.55M) is above average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: Mark's compensation has been consistent with company performance over the past year.


CEO

Mark Erlander (64 yo)

4.5yrs

Tenure

US$1,547,772

Compensatie

Dr. Mark Erlander, Ph D., is Chief Executive Officer of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since May 2020 and was its Chief Scientific Officer March 4, 2013 to April 2020. Dr. Erlan...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Mark Erlander
CEO & Director4.5yrsUS$1.55m0.053%
$ 78.5k
James Levine
Chief Financial Officer3.3yrsUS$917.72k0.13%
$ 192.3k
Fairooz Kabbinavar
Chief Medical Officer1.8yrsUS$1.26m0%
$ 0
Tod Smeal
Chief Scientific Officer2.8yrsUS$4.17m0%
$ 0
Elizabeth Anderson
VP of Finance & Administration9.3yrsgeen gegevensgeen gegevens
Brigitte Lindsay
Senior Vice President of Finance1.8yrsgeen gegevensgeen gegevens
Charles Monahan
Senior Vice President of Regulatory Affairs2.8yrsgeen gegevensgeen gegevens

2.8yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren management: CRDF's management team is considered experienced (2.8 years average tenure).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Mark Erlander
CEO & Director4.4yrsUS$1.55m0.053%
$ 78.5k
Charles Cantor
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Gary Pace
Independent Director4.6yrsUS$114.43k1.5%
$ 2.2m
K. Hirth
Member of Scientific Advisory Board10.3yrsgeen gegevensgeen gegevens
Paul Billings
Member of Scientific Advisory Board12yrsUS$35.85kgeen gegevens
Rodney Markin
Independent Chairman of the Board10.8yrsUS$154.43k0.067%
$ 99.5k
Carlo Croce
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Riccardo Dalla-Favera
Member of Scientific Advisory Board14.6yrsgeen gegevensgeen gegevens
Lale White
Independent Director4.6yrsUS$116.43k0.24%
$ 364.7k
Alberto Bardelli
Member of Scientific Advisory Board10.2yrsgeen gegevensgeen gegevens
Renee Tannenbaum
Independent Director3.4yrsUS$110.43k0.021%
$ 32.0k
Brunangelo Falini
Member of Scientific Advisory Board14.6yrsgeen gegevensgeen gegevens

10.2yrs

Gemiddelde duur

72yo

Gemiddelde leeftijd

Ervaren bestuur: CRDF's board of directors are seasoned and experienced ( 10.2 years average tenure).